Gogoro Inc vs Nuwellis Inc — how do they compare? Gogoro Inc trades at $3.86 (market cap $77.38M), while Nuwellis Inc trades at $2.85 (market cap $1.10M). The key difference: Gogoro Inc is far larger — about 70.3× Nuwellis Inc's market cap, and Gogoro Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| GGR | NUWE | |
|---|---|---|
Market Cap | $77.38M | $1.10M |
Sector | Technology | Technology |
52-Week High | $7.89 | $558.26 |
52-Week Low | $2.74 | $2.80 |
Enterprise Value | $379.83M | -$709.83K |
Signals from Pluang's Aura AI — not financial advice
Gogoro Inc. (GGR) trades at $3.86, up 1.58% on the day, but remains in a technically bearish trend. Fundamentally, the company reported Q1 2026 results highlighting improved margins and positive operating cash flow, though it continues to post significant net losses with a -24.68% net income margin. The analyst consensus is unanimously neutral with a 100% Hold rating, reflecting caution despite recent operational progress.
The outlook is mixed. Opportunities stem from Gogoro's growing battery-swapping subscriber base and expansion into new markets like Vietnam. However, significant risks persist, including sustained unprofitability, high cash burn with a net cash flow of -$46.57M in 2025, and negative shareholder returns evidenced by a -50.38% ROE. The stock's low P/S of 0.21 suggests the market has heavily discounted its growth prospects.
Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.
The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.
Trailing returns across standard periods
Latest headlines on both assets
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →